New cocktail of drugs shows promise against stomach cancer in early trial

NCT ID NCT04745988

Ongoing Disease control Sponsor: National Cancer Center Hospital East Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tests whether a combination of lenvatinib, pembrolizumab, and chemotherapy (FLOT) can shrink stomach tumors before surgery and prevent recurrence afterward. It involves 43 adults with untreated, non-metastatic stomach cancer. The main goal is to see how many patients have a major reduction in tumor cells after treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: lenvatinib, pembrolizumab, docetaxel, oxaliplatin, levofolinate
What this could lead to: If successful, this combination could shrink tumors before surgery and improve outcomes for gastric cancer patients.
What could go wrong: This is a small, early-phase trial with no control group. The drug combination may cause significant side effects and may not prove effective in larger studies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GASTRIC ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

gastric adenocarcinoma gastric cancer gastric neoplasm gastroesophageal junction adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GASTRIC CANCER

Contacts and locations

Locations

National Cancer Center Hospital East

Kashiwa, Chiba, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.